EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014

Olivier J Wouters, Aaron S Kesselheim, Jouni Kuha, Jeroen Luyten

Value in Health · 2024-10 · 27 (10) · 1373-1381

DOI: 10.1016/j.jval.2024.06.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2024-10. Verfasst von Olivier J Wouters und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy, London School of Economics and Political Science, London, England, UK. Electronic address: O.J.Wouters@lse.ac.uk. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Approval, Commerce. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aimed to analyze worldwide sales of new therapeutic agents and to estimate the time it takes for product sales to exceed industry-wide average drug development costs. METHODS: Data obtained from company reports were analyzed to track worldwide sales of new medicines approved by the US Food and Drug Administration from 1995 to 2014. All sales figures were reported in 2019 US dollars. Kaplan-Meier curves were used to evaluate the time it took for discounted product sales to exceed the average costs associated with developing 1 new drug (accounting for the costs of failed trials), using published estimates of these costs. RESULTS: Based on data for 361 of 558 new therapeutic agents approved over the study period (median follow-up 13.2 years), mean sales revenue per product was $15.2 billion through the end of 2019; the median was $6.7 billion. These products jointly generated global sales of $5.5 trillion since approval. Revenues were highly skewed, with the 25 best selling products (7%, 25 of 361) accounting for 38% of this amount ($2.1 trillion of $5.5 trillion). Approximately 47% of products had discounted sales that exceeded the estimated industry-wide average costs of development within 5 years of approval, and 75% within 10 years. After attributing potential production, marketing, and other costs, these numbers dropped to 21% of products within 5 years of approval, and 46% within 10 years. CONCLUSIONS: Sales of new medicines approved from 1995 to 2014 were highly skewed, but many products had net discounted sales that exceeded the industry-wide average costs of development within 10 years of approval. An understanding of how sales revenues accrue in the years after initial approval, alongside data on business costs, can inform discussions about how to incentivize private investment in innovation while ensuring affordable prices for patients and the healthcare system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationDrug ApprovalCommerceUnited StatesHumansDrug CostsDrug Industry

Stichwörter der Autor:innen

drug pricespharmaceutical policyresearch and developmentrevenues

Autor:innen und Institutionen

  • Department of Health Policy, London School of Economics and Political Science, London, England, UK. Electronic address: O.J.Wouters@lse.ac.uk.
  • Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Department of Statistics, London School of Economics and Political Science, London, England, UK.
  • Leuven Institute for Healthcare Policy, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.

Zitieren

APA

Wouters, O. J., Kesselheim, A. S., Kuha, J., & Luyten, J. (2024). Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014. Value in Health, 27(10), 1373-1381. https://doi.org/10.1016/j.jval.2024.06.015

Vancouver

Wouters OJ, Kesselheim AS, Kuha J, Luyten J. Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014. Value in Health. 2024;27(10):1373-1381. doi:10.1016/j.jval.2024.06.015

BibTeX
@article{Wouters2024,
  author = {Wouters, Olivier J and Kesselheim, Aaron S and Kuha, Jouni and Luyten, Jeroen},
  title = {Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014},
  journal = {Value in Health},
  year = {2024},
  volume = {27},
  number = {10},
  pages = {1373--1381},
  doi = {10.1016/j.jval.2024.06.015}
}
Kostenlos starten →